1-7 of 7
Angela Romanelli, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-136791
Published: 2020
Journal Articles

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Vinitha Mary Kuruvilla, MSc, Rebecca McCarthy, Qi Zhang, PhD, Callum M. Sloss, PhD, Patrick A. Zweidler-McKay, MD PhD, Angela Romanelli, PhD, Sharlene Adams, PhD, Marina Y Konopleva, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1375.
https://doi.org/10.1182/blood-2019-124963
Published: 2019
Journal Articles

Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)

Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jutta Deckert, PhD, Jenny Tsui, BS, Leanne Lanieri, BS, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 5125.
https://doi.org/10.1182/blood.V126.23.5125.5125
Published: 2015
Journal Articles

IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

Watkins M Krystal, MS, Russell Walker, MS, Nathan Fishkin, PhD, Charlene Audette, Yelena Kovtun, PhD, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 1366.
https://doi.org/10.1182/blood.V126.23.1366.1366
Published: 2015
Journal Articles

IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

Jutta Deckert, PhD, Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jenny Tsui, BS, Nemisha Dawra, BS, Yong Yi, MD, Jennifer A Coccia, BS, Leanne Lanieri, BS, Sharon Chicklas, BS, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 1548.
https://doi.org/10.1182/blood.V126.23.1548.1548
Published: 2015
Journal Articles

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Jutta Deckert, PhD, Jose F. Ponte, PhD, Jennifer A. Coccia, Leanne Lanieri, Sharon Chicklas, Yong Yi, Krystal Watkins, Rodrigo Ruiz-Soto, MD MSc, Angela Romanelli, PhD, Robert J. Lutz, PhD
Journal: Blood
Blood (2014) 124 (21): 3119.
https://doi.org/10.1182/blood.V124.21.3119.3119
Published: 2014
Journal Articles

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anastasios Stathis, MD, Arnold S. Freedman, MD, Ian W. Flinn, MD, Kami J. Maddocks, MD, Steven Weitman, MDPhD, Jesus G. Berdeja, MD, Alex V. Mejia, MD, Emanuele Zucca, MD, Rebecca Green, Angela Romanelli, PhD, Sybil H Zildjian, MPH, Rodrigo Ruiz-Soto, MD MSc, Lia Palomba, MD
Journal: Blood
Blood (2014) 124 (21): 1760.
https://doi.org/10.1182/blood.V124.21.1760.1760
Published: 2014